CALA - カリセラ・バイオサイエンシズ (Calithera Biosciences Inc.) カリセラ・バイオサイエンシズ

 CALAのチャート


 CALAの企業情報

symbol CALA
会社名 Calithera Biosciences Inc. (カリセラ・バイオサイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ケリセラ・バイオサイエンス(Calithera Biosciences Inc.)は、臨床段階の製薬会社である。同社は、腫瘍微小環境における重要な代謝経路を制御する腫瘍及び免疫細胞標的に対する低分子薬物の発見及び開発に焦点を当てる。同社は、細胞傷害性T細胞のような腫瘍細胞及びガンと戦う免疫細胞の代謝要求を利用する薬剤の開発に従事する。同社のリード製品候補であるCB-839は、腫瘍細胞における重要な酵素である。CB-1158は、血液学及び腫瘍学の適応症のために開発される。CB-1158は、酵素アルギナーゼの強力かつ選択的な経口生物学的利用可能阻害剤である。CB-839は、ヒトグルタミナーゼの選択的で可逆的かつ経口的に生体利用可能な阻害剤である。CB-1158は、免疫機構を介して作用することが実証されている同系マウス腫瘍モデルにおいて、単剤抗腫瘍活性を有する。CB-1158は、固形腫瘍患者の第I相臨床試験で試験される。   カリセラ・バイオサイエンシズは米国の臨床段階の医薬品会社。主に、がんの治療のために腫瘍代謝及び腫瘍免疫学を対象に低分子薬剤の発見・開発に重点を置く。製品候補には、腫瘍代謝において重要な酵素であるグルタミナ―ゼ抑制剤「CB-839」、そして、アルギナ―ゼ抑制剤などがある。本社はカリフォルニア州。   Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. Calithera is headquartered in South San Francisco, California.
本社所在地 343 Oyster Point Blvd. Suite 200 South San Francisco CA 94080 USA
代表者氏名 Susan M. Molineaux スーザンM.モリノー
代表者役職名 President Chief Executive Officer Co-Founder Director
電話番号 +1 650-870-1000
設立年月日 40238
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 73人
url www.calithera.com
nasdaq_url https://www.nasdaq.com/symbol/cala
adr_tso
EBITDA EBITDA(百万ドル) -35.29600
終値(lastsale) 5.46
時価総額(marketcap) 196491089.34
時価総額 時価総額(百万ドル) 197.57070
売上高 売上高(百万ドル) 36.76200
企業価値(EV) 企業価値(EV)(百万ドル) 56.15670
当期純利益 当期純利益(百万ドル) -33.32600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Calithera Biosciences Inc revenues increased 94% to $22.3M. Net loss increased 51% to $16.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Other Research and Development increase of 100% to $30.9M (expense) Stock-based Compensation in SGA increase of 63% to $1.9M (expense).

 CALAのテクニカル分析


 CALAのニュース

   Calithera Biosciences to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021  2021/07/29 11:00:00 Intrado Digital Media
SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a fully-integrated clinical-stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Companys second quarter 2021 financial results will be released on Thursday, August 5, 2021. Company management will host a conference call on Thursday, August 5, 2021 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
   Waldenstrom Macroglobulinemia Therapeutics Market Size, Key Opportunities, Strategic Assessment, Strong Revenue | Oprating Vendors: BeiGene(Beijing) Co.,Ltd, Calithera Biosciences, Inc., Celgene Co  2021/07/25 23:28:18 Jumbo News
The documented report on Global Waldenstrom Macroglobulinemia Therapeutics Market by Reports Globe aims to offer an organized and methodical strategy for important aspects that have affected the market in recent years and future market opportunities that companies can trust. It gives readers clear market research for better judgment and better decision making on whether or []
   Early Moves to Watch: Exxon Mobil Corporation (NYSE:XOM), Calithera Biosciences, Inc. (NASDAQ:CALA)  2021/07/20 22:29:42 Stock Equity
Exxon Mobil Corporation (NYSE:XOM) with the stream of 1.19% also noticed, India Calithera Biosciences, Inc. (NASDAQ:CALA) encountered a rapid change of 2.78% in the last hour of Tuesdays trading session. The post Early Moves to Watch: Exxon Mobil Corporation (NYSE:XOM), Calithera Biosciences, Inc. (NASDAQ:CALA) appeared first on Stocks Equity .
   Sector Percentage Losers: Nikola Corporation (NASDAQ:NKLA), Calithera Biosciences, Inc. (NASDAQ:CALA)  2021/07/14 23:00:55 Stock Equity
Nikola Corporation (NKLA) with the stream of -1.40% also noticed, India Calithera Biosciences, Inc. (CALA) encountered a rapid change of -2.59% in the last hour of Wednesdays trading session. Nikola The post Sector Percentage Losers: Nikola Corporation (NASDAQ:NKLA), Calithera Biosciences, Inc. (NASDAQ:CALA) appeared first on Stocks Equity .
   Traders shouldnt Staggering on this: Freeport-McMoRan Inc. (NYSE:FCX), Calithera Biosciences, Inc. (NASDAQ:CALA)  2021/07/12 22:55:48 Stock Equity
Freeport-McMoRan Inc. (FCX) with the stream of 0.08% also noticed, India Calithera Biosciences, Inc. (CALA) encountered a rapid change of -3.45% in the last hour of Mondays trading session. Freeport-McMoRan The post Traders shouldnt Staggering on this: Freeport-McMoRan Inc. (NYSE:FCX), Calithera Biosciences, Inc. (NASDAQ:CALA) appeared first on Stocks Equity .
   Early Moves to Watch: Exxon Mobil Corporation (NYSE:XOM), Calithera Biosciences, Inc. (NASDAQ:CALA)  2021/07/20 22:29:42 Stock Equity
Exxon Mobil Corporation (NYSE:XOM) with the stream of 1.19% also noticed, India Calithera Biosciences, Inc. (NASDAQ:CALA) encountered a rapid change of 2.78% in the last hour of Tuesdays trading session. The post Early Moves to Watch: Exxon Mobil Corporation (NYSE:XOM), Calithera Biosciences, Inc. (NASDAQ:CALA) appeared first on Stocks Equity .
   Sector Percentage Losers: Nikola Corporation (NASDAQ:NKLA), Calithera Biosciences, Inc. (NASDAQ:CALA)  2021/07/14 23:00:55 Stock Equity
Nikola Corporation (NKLA) with the stream of -1.40% also noticed, India Calithera Biosciences, Inc. (CALA) encountered a rapid change of -2.59% in the last hour of Wednesdays trading session. Nikola The post Sector Percentage Losers: Nikola Corporation (NASDAQ:NKLA), Calithera Biosciences, Inc. (NASDAQ:CALA) appeared first on Stocks Equity .
   Traders shouldnt Staggering on this: Freeport-McMoRan Inc. (NYSE:FCX), Calithera Biosciences, Inc. (NASDAQ:CALA)  2021/07/12 22:55:48 Stock Equity
Freeport-McMoRan Inc. (FCX) with the stream of 0.08% also noticed, India Calithera Biosciences, Inc. (CALA) encountered a rapid change of -3.45% in the last hour of Mondays trading session. Freeport-McMoRan The post Traders shouldnt Staggering on this: Freeport-McMoRan Inc. (NYSE:FCX), Calithera Biosciences, Inc. (NASDAQ:CALA) appeared first on Stocks Equity .
   The Daily Biotech Pulse: Lilly, Morphic''s Positive Data At ECCO, Humanigen''s COVID Treatment Gets Expedited Review In UK, TransCode IPO  2021/07/09 11:36:16 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO ) ( moved on positive analyst action) Ambrx Biopharma Inc. (NYSE: AMAM ) AtriCure, Inc. (NASDAQ: ATRC ) Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) BioLife Solutions, Inc. (NASDAQ: BLFS ) Edwards Lifesciences Corporation (NYSE: EW ) Novo Nordisk A/S (NYSE: NVO ) Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 8) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) ADMA Biologics, Inc. (NASDAQ: ADMA ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) (announced positive Phase 2 data for non-alcoholic steatohepatitis drug) Allogene Therapeutics, Inc.
   Calithera to Present at the Jefferies 2021 Virtual Healthcare Conference  2021/05/27 00:00:00 BioSpace
Calithera Biosciences, Inc., a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced that Susan Molineaux, Ph.D., the companys founder, president and chief executive officer, will present at the Jefferies 2021 Virtual Healthcare Conference on Friday, June 4, 2021 at 9:00 am ET.
   Calithera to Present at the Jefferies 2021 Virtual Healthcare Conference  2021/05/27 00:00:00 BioSpace
Calithera Biosciences, Inc., a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced that Susan Molineaux, Ph.D., the companys founder, president and chief executive officer, will present at the Jefferies 2021 Virtual Healthcare Conference on Friday, June 4, 2021 at 9:00 am ET.
   Calithera, Antengene Announce Licensing Agreement For CB-708 In Cancer Settings  2021/05/17 14:08:02 Benzinga
Calithera Biosciences Inc (NASDAQ: CALA ) and Antengene Corporation Ltd have announced an exclusive, worldwide license agreement for the development and commercialization of CB-708. CB-708 is a highly potent, Full story available on Benzinga.com
   Calithera Biosciences and Antengene ink worldwide exclusive license agreement  2021/05/17 12:29:55 Seeking Alpha
   Calithera, Antengene Ink Exclusive Global License Deal For Development Of CB-708 - Quick Facts  2021/05/17 12:22:34 Business Insider Markets
(RTTNews) - Biotechnology company Calithera Biosciences, Inc. (CALA) and Hong Kong-based Antengene Corp. announced an exclusive, worldwide license agreement for the development and commercialization of CB-708, Calithera''s small molecule inhibitor of CD73. CB-708 is a highly potent, selective, orally-bioavailable small molecule inhibitor of CD73.
   Calithera Biosciences and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708  2021/05/17 00:00:00 BioSpace
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, and Antengene Corporation, Ltd. (SEHK: 6996.HK), a leading clinical-stage R&D driven biopharmaceutical company focused on innovative medicines for oncology and other life-threatening diseases

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 カリセラ・バイオサイエンシズ CALA Calithera Biosciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)